Charles River Laboratories International, Inc. CRL
- Market cap
- $14.1B
- P/E
- 0.0×
Follow CRL
Charles River Laboratories International, Inc. (CRL) Return on invested capital
Charles River Laboratories International, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 1.07%, up 0.8 percentage points from fiscal 2025 (0.31%). Over the past ten years it has ranged from 0.31% (fiscal 2025) to 8.88% (fiscal 2017) — the current reading is the lowest in ten years. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Annual
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.31% | (2.27) |
| FY2024 | 2.58% | (3.88) |
| FY2023 | 6.46% | (0.93) |
| FY2022 | 7.39% | 0.01 |
| FY2021 | 7.38% | 0.39 |
| FY2020 | 6.99% | 0.32 |
| FY2019 | 6.67% | (0.75) |
| FY2018 | 7.42% | (1.46) |
| FY2017 | 8.88% | 1.29 |
| FY2016 | 7.59% | (1.11) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| DGX Quest Diagnostics Incorporated compare | 7.94% |
| QGEN QIAGEN N.V. compare | 6.62% |
| LH Labcorp Holdings Inc. compare | 6.50% |
| RVTY Revvity Inc. compare | 2.38% |
| ICLR ICON PLC compare | 1.57% |
| CRL Charles River Laboratories International, Inc. | 1.07% |
| MEDP Medpace Holdings, Inc. compare | 0.00% |
| TWST Twist Bioscience Corporation compare | −30.8% |
| GH Guardant Health, Inc. compare | −129.7% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on CRL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement